Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer

• Status: Recruiting
• Trial end date: 2021-01-30
• Target enrollment: 0
• Participant gender: Female

Summary

Tranexamic acid has been used in surgery for more than 30 years. It's effect on reducing bleeding and blood transfusing has been demonstrated.

In our hospital, the amount of cytorsductive surgery for ovarian cancer is big. During the perioperation , bleeding probability is high, and the supply of blood products is limited. In order to reduce bleeding, we're planning to use tranexamic acid in the operations.

In this experiment, we will observe the efficacy of tranexamic acid in cytoreductive surgery for ovarian cancer, find the best dosage which can reach the desired effect, and the possible side-effect.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Jun Zhang
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

1. sign the informed consent

2. Aged 20-70 years

3. ovarian cancer patients, staged IIIB - C or above

3) ASA I - II

Exclusion Criteria:

1. tranexamic acid allergy

2. pregnancy and lactation

3. only lymph node metastasise

4. history of mental disorder, immune system disorder

5. history of epilepsy, dyschromatopsia

6. arrhythmia

7. history of renal insufficiency

8. thrombosis related disease

9. Hb < 90 g/dL

10. using anticoagulant drugs (not including aspirin discontinuation 1 week

11. having participated in other clinical trials, or refusing to join the research.